focus -WSS

focus

author：hotspot 2025-09-27 10:03:54 - browse：4

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： What to do when lifesaving products contribute to climate change

hotspot

WSS

What to do when lifesaving products contribute to climate change

Biotech investment managers search for lucrative opportunities

ReNAgade cuts staff seven months after raising $300 million

Surgeons perform first xenotransplant using CRISPR'd pig kidney

J&J to emphasize cancer drugs, stop much of its vaccine research

Texas board proposes rules on abortion law emergency exemption

focus

focus

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth’s Optum accused of antitrust violations in California

BioMarin wins approval for gene therapy to treat hemophilia A

Testing GLP

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Rep. Raul Ruiz on the physician shortage and more

Walensky prepares to leave CDC — and Congress — behind

'Patient friction coefficient' can gauge a clinical trial's patient burden

How one medical school became remarkably diverse

Testing GLP

knowledge

CDC director unscathed in first congressional testimony

How to pay for weight loss drugs and save Medicare

Bring on the sabbaticals for nurses

FDA investigates CAR

J&J to emphasize cancer drugs, stop much of its vaccine research

Diabetes management: Digital health tools fall short, study says

focus

hotspot

hotspot

focus